Profile
ACHL VRTX VRNA REGN ALNY ARGX
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Verona Pharma plc Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $108.04B $72.68B $68.01B $60.75B $50.28B
Employees 0.20K 6.10K 0.21K 15.16K 2.23K 1.60K
CEO Iraj Ali Reshma Kewalramani FASN, David S. Zaccardelli Leonard S. Schleifer Yvonne L. Greenstreet Timothy Van Hauwermeiren EMBA,
Ratings
ACHL VRTX VRNA REGN ALNY ARGX
Quant Rating Score 3 3 1 4 1 3
Quant Rating Neutral Neutral Strong Sell Buy Strong Sell Neutral
Trading
ACHL VRTX VRNA REGN ALNY ARGX
Last Close $1.48 $417.21 $106.91 $652.91 $481.59 $821.97
High 52 $1.49 $516.74 $106.91 $922.79 $491.09 $849.46
Low 52 $0.97 $366.54 $33.93 $482.92 $224.58 $532.27
Price vs. 52 Week High -0.67 % -19.26 % 0 % -29.25 % -1.93 % -3.24 %
Price vs. 52 Week Low 52.58 % 13.82 % 215.09 % 35.2 % 114.44 % 54.43 %
Total Return
ACHL VRTX VRNA REGN ALNY ARGX
1 Month Return 0 % 6.53 % 0.17 % 16.12 % 5.63 % 11.42 %
3 Month Return 0 % -11.07 % 1.68 % 17.71 % 41.85 % 37.25 %
6 Month Return 0 % -18.11 % 48.2 % 9.05 % 82.89 % 27.56 %
9 Month Return 32.14 % -4.83 % 86.77 % -4.42 % 73.76 % 23.48 %
YTD Return 29.82 % 3.6 % 130.21 % -8.34 % 104.66 % 33.65 %
1 Year Return 45.1 % -12.18 % 212.69 % -29.25 % 71.09 % 48.99 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX VRNA REGN ALNY ARGX
Dividend Yield Percentage (TTM) - - - 0.4 % - -
Dividend Paid and Capex Coverage Ration (TTM) -480.78 % 11.09 % -147.93 % 4.25 % -0.43 % 65.28 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) - - - 6.06 % - -
Growth
ACHL VRTX VRNA REGN ALNY ARGX
Asset Growth -26.73 % -0.87 %
Gross Profit Growth -28.3 % 10.25 %
Revenue Growth - 11.66 %
Revenue 3 Year - 45.6 %
Revenue 5 Year - 163.93 %
Revenue 10 Year - 1632.15 %
EBIT Growth -5.82 % -93.69 %
Net Income Growth 2.12 % -114.8 %
Net Income 3 Yeari Growth Per Share -113.25 % -122.89 %
Net Income 5 Yeari Growth Per Share 86.28 % -145.38 %
Net Income 10 Yeari Growth Per Share 86.28 % 33.84 %
Operating Income Growth 3.99 % -106.08 %
Operating Cash Flow Growth (CFG) 18.62 % -113.93 %
Operating 3 Year CFG -94.98 % -118.65 %
Operating 5 Year CFG -8546.04 % -131.3 %
Operating 10 Year CFG -8546.04 % 12.43 %
EPS Growth 4.4 % -114.8 %
EPS Diluted Growth 4.4 % -114.97 %
Book Value Per Share -29.25 % -6.59 %
Share Holder 3 Year Equity Growth Per Share -23.6 % 62.6 %
Share Holder 5 Year Equity Growth Per Share -84.77 % 168.85 %
Share Holder 10 Year Equity Growth Per Share -84.77 % 1292.6 %
Dividend Per Share Growth - -
Dividend 3 Year Growth Per Share - -
Dividend 5 Year Growth Per Share - -
Dividend 10 Year Growth Per Share - -
Debt Growth -46.19 % 116.42 %
Free Cash Flow Growth 26.1 % -124.1 %
Updated On 31 Dec 2023 31 Dec 2024
Profitability
ACHL VRTX VRNA REGN ALNY ARGX
Gross Profit Margin TTM - 86.11 % 95.15 % 85.39 % 83.64 % 65.82 %
Return on Assets TTM -29.33 % 15.13 % -14.17 % 11.4 % -6.99 % 15.06 %
Return on Equity TTM -32.91 % 22.14 % -38.66 % 15.31 % -274.21 % 18.96 %
Return on Capital Employed TTM -36.67 % 19.72 % -10.74 % 10.32 % -5.52 % 5.04 %
Net Income Per EBT TTM 100.01 % 83.16 % 111.3 % 88.98 % 84.06 % 237.3 %
EBT Per Ebit TTM 94.13 % 111.48 % 130.22 % 139.5 % 210.66 % 147.38 %
EBIT Per Revenue TTM - 34.36 % -25.27 % 25.89 % -7.32 % 13.47 %
Cash Flow To Debt Ratio TTM -0.48 % 251.83 % -29.66 % 187.43 % -1.2 % 932.29 %
Receivables Turnover TTM - 6.03 2.55 2.51 4.34 1.91
Payables Turnover TTM 0.28 3.59 3.13 2.3 3.93 0.9
Inventory Turnover TTM - 1.06 1.25 0.64 5.62 2.26
Fixed Asset Turnover TTM - 431.08 % 8642.22 % 284.82 % 355.68 % 5009.77 %
Asset Turnover TTM - 47.51 % 38.7 % 35.47 % 53.92 % 31.97 %
Operating Cash Flow Per Share TTM - 14.98 -0.85 48.94 -0.12 5.67
Free Cash Flow Per Share TTM - 13.63 -0.85 40.09 -0.4 5.58
Cash Per Share TTM 212.86 % 2486.48 % 511.44 % 8148.65 % 2203.63 % 5536.58 %
Operating Cash Flow Sales Ratio TTM - 33.68 % -32.7 % 35.59 % -0.63 % 17.54 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.21 % 90.99 % 100.75 % 81.92 % 335.21 % 98.47 %
Cash Flow Coverage Ratios TTM -0.48 % 251.83 % -29.66 % 187.43 % -1.2 % 932.29 %
Price To Free Cash Flows Ratio TTM -3507.15 30.87 -995.27 16.37 -1166.22 132.81
Price To Operating Cash Flows Ratio TTM -3456.91 28.12 -126.33 13.34 -3867.41 151.69
Price Cash Flow Ratio TTM -3456.91 28.12 -126.33 13.34 -3867.41 151.69
Income Statement (TTM)
ACHL VRTX VRNA REGN ALNY ARGX
Revenue $0B $11.02B $0.03B $14.2B $2.25B $2.19B
Gross Profit $-0B $9.49B $0.03B $12.23B $1.92B $1.96B
Gross Profit Ratio 0% 86.11% 93.89% 86.13% 85.62% 89.62%
EBITDA $-0.07B $0.49B $-0.12B $5.32B $-0.18B $0.11B
Net Income $-0.07B $-0.54B $-0.14B $4.41B $-0.28B $0.83B
EPS Diluted -1.74 -2.08 -1.73 38.34 -2.18 12.78
Balance Sheet (MRQ)
ACHL VRTX VRNA REGN ALNY ARGX
Long Term Debt $0B $1.66B $0.12B $2.7B $1.25B $0.03B
Total Liabilities $0.02B $6.12B $0.27B $8.41B $4.17B $0.7B
Total Equity $0.14B $16.41B $0.2B $29.35B $0.07B $5.5B
Total Investments $0B $6.65B $0.02B $15.42B $1.73B $1.93B
Total Debt $0B $1.75B $0.12B $2.7B $1.3B $0.04B
Total Assets $0.16B $22.53B $0.47B $37.76B $4.24B $6.2B
Cash Flow Statement (TTM)
ACHL VRTX VRNA REGN ALNY ARGX
Net Income $-0.07B $-0.54B $-0.17B $4.41B $-0.28B $0.83B
Inventory $0B $-0.52B $-0.01B $-0.62B $0.01B $-0.1B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $-0.12B $4.42B $-0.01B $-0.08B
Capital Expenditure $-0B $-0.3B $-0B $-0.76B $-0.03B $-0.07B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 33.05
AARD Aardvark Therapeutics, Inc. Common Stock 10.8826
ABCL AbCellera Biologics Inc. 5.4888
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.2869
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.2776
ABPWW 0.0143
ABSI Absci Corporation 4.235
ABUS Arbutus Biopharma Corporation 4.875
ABVC ABVC BioPharma, Inc. 2.85
ABVX Abivax SA American Depositary Shares 104.208
ACAD ACADIA Pharmaceuticals Inc. 22.83
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.7963
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 5.045
ACIU AC Immune SA 3.625
ACLX Arcellx, Inc. 87.755
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 158.14
BIB ProShares Ultra Nasdaq Biotechnology 0 69.88
IBBQ Invesco Nasdaq Biotechnology ETF 0 26.53
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 7.7575
Unlock